Letter Regarding "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib"

J Thorac Oncol. 2024 Aug;19(8):e29-e30. doi: 10.1016/j.jtho.2024.06.014.

Authors

Sophie M Ernst¹, Jan H von der Thüsen², Hendrikus J Dubbink², Anne-Marie C Dingemans³

Affiliations

¹ Department of Respiratory Medicine, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
² Department of Pathology and Clinical Bioinformatics, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands.
³ Department of Respiratory Medicine, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands. Electronic address: [email protected].

PMID: 39112013
DOI: 10.1016/j.jtho.2024.06.014

No abstract available

Publication types

Letter

MeSH terms

Carcinoma, Non-Small-Cell Lung* / blood
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Carcinoma, Non-Small-Cell Lung* / pathology
Circulating Tumor DNA* / blood
Circulating Tumor DNA* / genetics
Humans
Lung Neoplasms* / blood
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Lung Neoplasms* / pathology
Mutation*
Proto-Oncogene Proteins p21(ras)* / genetics

Substances

Circulating Tumor DNA
Proto-Oncogene Proteins p21(ras)
KRAS protein, human